Equities Analysts Offer Predictions for Fate Therapeutics Inc’s FY2019 Earnings (NASDAQ:FATE)
Fate Therapeutics Inc (NASDAQ:FATE) – Equities research analysts at Piper Jaffray Companies decreased their FY2019 EPS estimates for shares of Fate Therapeutics in a research note issued on Tuesday, November 5th. Piper Jaffray Companies analyst E. Tenthoff now expects that the biopharmaceutical company will earn ($1.41) per share for the year, down from their previous estimate of ($1.36). Piper Jaffray Companies currently has a “Overweight” rating and a $28.00 target price on the stock. Piper Jaffray Companies also issued estimates for Fate Therapeutics’ Q4 2019 earnings at ($0.35) EPS, Q1 2020 earnings at ($0.35) EPS, Q2 2020 earnings at ($0.37) EPS, Q4 2020 earnings at ($0.41) EPS, FY2020 earnings at ($1.50) EPS, Q1 2021 earnings at ($0.42) EPS, Q2 2021 earnings at ($0.46) EPS, Q3 2021 earnings at ($0.47) EPS and FY2021 earnings at ($1.85) EPS.